Awardee OrganizationUNIVERSITY OF ILLINOIS AT CHICAGO
Description
Abstract Text
ABSTRACT
Despite advances in HIV diagnostics, care and prevention strategies, infection rates among adolescent and young adult
sexual and gender minorities (SGM) continue to rise in the United States (US). There is an urgent need to describe the
epidemiology and trajectories of HIV acquisition in this population and to offer age and culturally appropriate scalable
prevention interventions to those at highest risk of infection in the US. This project will engage and retain young SGM in
an innovative longitudinal cohort, enroll them in a dynamic established digital health retention platform (HMP;
HealthMPowerment), monitor HIV risk and prevention behaviors and explore the socioecological factors that influence
the use of new HIV prevention technologies (UG3 phase), while also allowing targeted testing of novel digital health
interventions (UH3 phase). We will also test the efficacy of expanding the core version of HMP (HMP Basic) by adding
adherence tools (HMP Enhanced) for those who are on PrEP or ART to improve adherence and persistence. In Aim 1,
we will enroll and retain a large (n=6000; 3000/year), diverse cohort of sexually active, SGM adolescents and young
adults, ages 13-34, using innovative digital recruitment, engagement and retention strategies. Over the course of the study,
we will longitudinally characterize the sexual behavior, HIV transmission risk, and PrEP uptake trajectories of SGM
youth utilizing epidemiological trajectory analyses to identify the most effective points of intervention (Aim 2). For Aim
3, we will launch a randomized clinical trial to examine the efficacy of HMP Enhanced to improve PrEP adherence
among HIV-negative youth (n ≥750) and ART adherence among HIV-positive youth (n ≥150) compared to HMP Basic.
Finally, we will maximize the productivity of the cohort by testing new and innovative digital health devices, HIV/STI
diagnostics and interventions, informed by the previous aims as well as emerging NIH prevention priorities (Aim 4). Our
investigative team has decades of experience with recruitment, prevention and care of SGM youth and large-scale
longitudinal cohort studies. This study will capitalize upon productive existing partnerships and digital health expertise to
articulate the drivers of the ongoing HIV epidemic among the most vulnerable populations in the US in order to identify
the most effective, expeditious and scalable strategies to address this ongoing public health crisis.
Public Health Relevance Statement
PROJECT NARRATIVE
The proposed research project has high relevance to public health because it focuses on sexual and gender minority
(SGM) youth, particularly Black and Latinx, gay, bisexual and other men who have sex with men (GBMSM) and
transgender and gender diverse populations that have been devastated by the HIV epidemic in the United States. This
study supports the National HIV/AIDS Strategy’s focus on HIV treatment and prevention for the most impacted US
populations. The development of a large, digital community of SGM youth also aligns with the NIH’s focus on reducing
stigma and addressing co-morbidities and barriers to adherence and retention in HIV care and preventative services.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS preventionAddressAdherenceAdolescent and Young AdultAgeAreaArticulationAwardBehaviorBiologicalBisexualBlack raceCaringClinicClinical TrialsCognitiveCohort StudiesCommunitiesDevelopmentDevicesDiagnosticDiscriminationElectronicsEnrollmentEpidemicEpidemiologyExclusionFriendsGaysGeographyHIVHIV InfectionsHIV SeronegativityHIV SeropositivityHIV riskHIV/AIDSHIV/STDHuman ResourcesIncidenceIndividualInjectableInterventionLatinxLongitudinal cohortLongitudinal cohort studyMedicalMethodologyMonitorOralParticipantPersonsPhasePopulationPopulation HeterogeneityPreventionPrevention strategyPreventive serviceProductivityPublic HealthPublished CommentRecording of previous eventsResearchResearch Project GrantsRiskSex BehaviorSexual and Gender MinoritiesSiteSocial ChangeStructural RacismTechnologyTestingTimeUnited StatesUnited States National Institutes of HealthViralVulnerable PopulationsYouthcare systemsclinical research sitecohortcomorbiditycostdesigndigitaldigital healthefficacy evaluationefficacy testingepidemiological modelethnic minorityexperiencegender diversegender minoritygender minority youthhealth inequalitieshigh riskimprovedinfection rateinfection riskinnovationinterestmen who have sex with menmobile applicationnonbinarynovelpre-exposure prophylaxispreventive interventionpsychologicracial minorityrandomized, clinical trialsrecruitresponseretention rateself testingsexual minoritysexual minority communitysexual minority youthsexually activesocial stigmatooltransfemininetransgendertransmasculinetransmission processuptake
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
098987217
UEI
W8XEAJDKMXH3
Project Start Date
19-May-2022
Project End Date
21-March-2025
Budget Start Date
01-August-2024
Budget End Date
21-March-2025
Project Funding Information for 2024
Total Funding
$1,627,431
Direct Costs
$1,793,695
Indirect Costs
$365,120
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$877,431
2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$750,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 4UH3AI169631-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 4UH3AI169631-03
Patents
No Patents information available for 4UH3AI169631-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 4UH3AI169631-03
Clinical Studies
No Clinical Studies information available for 4UH3AI169631-03
News and More
Related News Releases
No news release information available for 4UH3AI169631-03
History
No Historical information available for 4UH3AI169631-03
Similar Projects
No Similar Projects information available for 4UH3AI169631-03